At the beginning of the U.S. stock market on August 14 (Friday), curevac, a German start-up biotechnology company, which is studying health event vaccines, officially launched < / P > < p > curevac was established in 2000, and its products include candidate drugs cv8102 and cv7202. At present, cv8102 is in the first phase of solid tumor trials, and cv7202 is in the first phase of rabies vaccine trial. The company is also promoting its mRNA vaccine program for the health event virus (sars-cov-2), which launched a phase I trial in healthy volunteers in June 2020, and the results are expected to be available in the fourth quarter of 2020. GlaxoSmithKline said in July that it would make an equity investment of 130 million pounds in curevac to acquire a nearly 10% stake to strengthen its business in the fight against health incidents. In addition, the German government bought a 300 million euro stake in curevac in June, which the company said the United States was trying to acquire.